Calendario›TRAW›irinotecan and ON 01910.Na
irinotecan and ON 01910.Na
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Ensayo de Traws Pharma, Inc. en Hepatoma · Advanced Solid Tumor (del registro, en inglés).
Más ensayos de: Tumor sólido avanzado.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 16
- Centros
- 1
- Fin del objetivo primario
- jul 2011
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en jun 2008.
Qué mide
maximum tolerated dose (6 - 12 months) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroStudies done in the laboratory have demonstrated beneficial effects of ON 01910.Na, a new, unapproved drug, when it is used in combination either irinotecan and oxaliplatin, two approved, extensively used anti-cancer drugs. In these laboratory studies, mice implanted with cells (Bel-7402 cells) that came from a human tumor were used as a model of liver cancer. In mice that were not treated, the Bel-7402 cells formed very large tumors. In mice that were treated with ON 01910.Na, irinotecan or oxaliplatin alone, growth of tumors was reduced compared to the untreated group. When a combination of ON 01910.Na and irinotecan or of ON 01910.Na and oxaliplatin was used to treat the mice, tumor growth was completely inhibited. Another observation in these studies was that toxicity did not increase when the combinations were used. These results and similar results from other studies support the hypothesis that a combination of ON 01910.Na and irinotecan or of ON 01910.Na and oxaliplatin would be an effective and tolerable treatment for liver and other types of cancer. The primary objective of this phase 1 study is to find out what doses of ON 01910.Na in combination with either irinotecan or oxaliplatin are safe and tolerable in patients with liver and other types of cancer.
Más ensayos de TRAW
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Ratutrelvir | Fase 2 | Reclutando pacientes | feb 2026 (prevista, ya pasada: sin actualizar en el registro) |
| TRX-100 | Fase 1 | Reclutando pacientes | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| TRX-100 | Fase 2 | Aún sin reclutar | nov 2026 (prevista) |
| TRX-100 | Fase 2 | En marcha, sin reclutar | dic 2026 (prevista) |
| Narazaciclib | Fase 1/2 | Sin noticias del promotor | ene 2026 (prevista, ya pasada: sin actualizar en el registro) |
| TRX-100 | Fase 1 | Completado | ene 2025 (real) |
Todos los de TRAW, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00861783), actualizada en jun 2017.